International Journal of Cancer · 2006 · 107 citations · 28 references
MedicineImmunologyInfectious DiseasesEpidemiologic MethodsEpidemiologyTransplant SurgeryGraft-versus-host DiseaseKaposi SarcomaPost-transplant ComplicationsTransplant PathologyHuman Herpesvirus 8Immunosuppression RegimensInfection Risk Under ImmunosuppressionInfection Transmission RiskMalignancy Risk Under ImmunosuppressionRecipient Risk StratificationRiskTransplant-associated Infections
Kaposi's sarcoma (KS) risk is high in immunosuppressed transplant recipients. KS develops in recipients with pre-existing infection with human herpesvirus 8 (HHV-8), the causative agent for KS, but it can also occur in recipients infected by donors. The relative importance of these sources of infection in recipients in the United States is unknown. We report recipient and donor characteristics associated with KS among transplant recipients in the United States. KS risk, after solid organ transplantation during 1993-2003, was analyzed using data from the Organ Procurement and Tissue Network. Associations were determined using proportional hazards regression. Sixtyfive KS cases were identified among 234,127 transplants (incidence 8.8 per 100,000 person-years). Most cases occurred in the first 2 years after transplantation (incidence 12.5 per 100,000 person-years). KS risk increased steadily with recipient age (p(trend) < 0.001) and was associated with the recipient being male (HR 1.8, 95% CI, 1.0-3.2), Hispanic (2.1, 1.1-3.8) and a non-U.S. citizen (3.9, 1.8-8.6). Mismatch at the HLA-B locus, but not at HLA-A or HLA-DR loci, was associated with heightened risk (HR 3.6, 95%CI 1.1-11 for 1-2 vs. 0 HLA-B mismatches). KS was unrelated to donor characteristics and was not significantly related to use of specific antirejection medications. Our study found that KS incidence was low among transplant recipients in the United States, but it was associated with recipient age, sex and citizenship, perhaps reflecting pre-existing HHV-8 infection. The high KS risk immediately posttransplant and in persons with HLA-B mismatch highlights the role of immunosuppression and/or immune stimulation in KS pathogenesis.
28
Sirolimus for Kaposi's Sarcoma in Renal-Transplant Recipients
Giovanni Stallone, Antonio Schena, Barbara Infante et al. · New England Journal of Medicine · 2005 · 984 citations · Full text
Medicine, Immunology, Nephrology +12
Cancer risk after renal transplantation in the nordic countries, 1964–1986
Sven Arvid Birkeland, Hans H. Storm, L.U. Lamm et al. · International Journal of Cancer · 1995 · 614 citations
Medicine, Immunology, Oncology +12
Kaposi's sarcoma in recipients of renal transplants
Andrew R. Harwood, David Osoba, Sophie L. R. Hofstader et al. · The American Journal of Medicine · 1979 · 419 citations
Medicine, Immunology, Nephrology +11